gastrointestinal tumours, non-colorectal

CONSECUTIVE COMPLETE RADICAL SURGERY (CRS) PLUS HYPERThERMIC INTRAPERITONEAL CHEMOTHERAPY (HIPEC) PROCEDURES IN PATIENTS WITH PERITONEAL CARCINOMATOSIS (PC). CLINICAL RESULTS AND SURVIVAL ACCORDING TO MALIGNANCY TYPE (SPAIN)

I. Ramos1, O. Crusellas Maña2, J. Castellvi3, G. Galofre1, G. Soler2, F. Losa4, M. Martín5, P. Barrios1
1Surgery, CSI, Sant Joan Despí, SPAIN
2General Surgery, Hospital Sant Joan Despí Moises Broggi, Barcelona, SPAIN
3Medical Oncology, ICO, Hospitalet, SPAIN
4Medical Oncology, Hospital General de l’Hospitalet, Barcelona, SPAIN
5Epidemiology, CSI, Sant Joan Despí, SPAIN

Aim: CRS + HIPEC offers clinical benefits over conventional treatment in certain types of Peritoneal Surface Malignancies (PSM). This type of treatment is performed with curative intent, and considered standard therapy in pseudomyxoma peritonei, peritoneal mesothelioma and PC from colorectal and appendiceal tumors. It is recommended in primary as well as recurrent ovarian tumors. There is consensus in PC of gastric origin and other infrequent PSM. International Health Agencies recommend using this treatment modality at highly specialized centers, by an experience team able to ensure efficacy and safety results, under carefully controlled research programs, regularly evaluated.

Methods: From September 06 to April 14, 466 pts with PC from different PSM types have been treated with 513 CRS + HIPEC procedures. 200 pts had PC from colon tumors, 99 pseudomyxoma peritonei, 78 recurrent ovarian cancer, 26 gastric PC, 21 appendiceal tumors, 16 malignant peritoneal mesothelioma, 11 no-GIST peritoneal sarcomatosis, 8 rectum tumors, 5 urachus origin and 4 from small bowel tumors. 79.9% had chemotherapy prior to CRS + HIPEC, and 91.2% prior surgery. Mean PCI 13/39. CRS achieved in 95.4%. HIPEC adjusted the type of chemotherapy agent and exposure time to the PSM. Mean HIPEC temp: 42.5°C. Mean op time was 368 min. Mean ICU and hospital stays, 2d and 13.1 d, respectively.

Results: A third party is currently auditing these preliminary results. Morbidity: 25.5%. Reoperations: 3.4%. Anastomotic dehiscence: 0%. Hospital readmissions: 4.6%. 30-day mortality: 1 pt Mean follow up: 24.7m. 1y predicted survival: 90.3%. Mean sv: 46.2m. Colon PC: sv probability at 12m: 91.5%, 3y sv 48.3%, 5y sv: 32%. Mean sv: 41.3m. Pseudomyxoma peritonei: 1y sv: 96.9%, 3y sv: 87.4%. Mean sv: 67m. Recurrent ovarian cancer: 1y sv: 93.1%. Mean sv: 41.6m and median sv: 45.4m. Appendiceal PC: 1y sv: 84%. Mean sv: 36.8 and median sv: 35.2m. Gastric PC: 1y sv: 66.3%. Median sv: 27.2m Malignant peritoneal mesothelioma: sv probability at 12m: 79.3%. Mean sv: 35.4m and 5y predicted sv: 41%.

Conclusions: Our experience confirmed that CRS + HIPEC offers clinical benefits over conventional treatment in certain types of Peritoneal Surface Malignancies (PSM), as described in other series.

Disclosure: All authors have declared no conflicts of interest.